Jun Wang , jun li

Animal Science Research Center, Cuixi Academy of Biotechnology, Zhuji, 311800, Zhejiang, China
Author    Correspondence author
International Journal of Molecular Veterinary Research, 2024, Vol. 14, No. 4   
Received: 25 Feb., 2024    Accepted: 10 Mar., 2024    Published: 01 Apr., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Feline infectious diseases, caused by various viral pathogens such as Feline Leukemia Virus (FeLV), Feline Immunodeficiency Virus (FIV), and Feline Infectious Peritonitis Virus (FIPV), pose significant health challenges to domestic and wild cats. This study explores the current state of antiviral therapy development for these diseases, delving into the mechanisms of viral replication and host interactions, the efficacy and limitations of existing antiviral treatments, and emerging therapeutic approaches. These include targeting viral proteins, host-directed therapies, gene editing, and broad-spectrum antiviral drugs. A case study focusing on the development of GS-441524 for FIP highlights the successes and challenges of implementing new therapies. The study also discusses the importance of personalized medicine, the potential of combination therapies, and strategies to combat drug resistance. This research underscores the importance of continued innovation and collaboration in veterinary medicine to improve outcomes for cats affected by viral diseases.

Feline infectious diseases; Antiviral therapy; Feline leukemia virus (FeLV); Feline immunodeficiency virus (FIV); Feline infectious peritonitis (FIP); Veterinary medicine